Nutrients · 19 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This prospective observational study of 110 newly diagnosed breast cancer patients found that 64.8% were vitamin D deficient. Vitamin D deficiency was associated with supplement use and season, but the study did not support it as a main prognostic factor for breast cancer.
This pilot study analyzed serum 25-hydroxyvitamin D (25(OH)D) levels in 110 non-metastatic breast cancer patients at diagnosis. The median serum 25(OH)D level was 24 ng/mL, with 64.8% of patients classified as deficient. Vitamin D levels were significantly higher in patients taking supplements and during the summer season. A significant association was found where patients with moderate vitamin D deficiency were less likely to have triple-negative breast cancer. However, no significant associations were observed between 25(OH)D levels and other prognostic factors like Ki67, grading, tumor stage, or other subtypes. The study concludes that vitamin D deficiency is common in this population and warrants clinical monitoring, but its results do not support deficiency as a primary prognostic factor for breast cancer. Limitations include a small sample size and retrospective reporting of lifestyle factors.
